Statera Biopharma Inc. (NASDAQ:STAB) Stock Sees Bullish Action As Company Plans Acquire Statera’s TLR5 Agonist Platform To

April 14, 2022

Statera Biopharma Inc. (NASDAQ:STAB) was up 17% after entering a strategic agreement with Coeptis Therapeutics Inc. (OTCMKTS:COEP). Under the terms of the strategic agreement, Coeptis will purchase Statera’s toll-like receptor 5 (TLRs) agonists platform that includes entolimod. Trading Data      On Wednesday, STAB stock surged 17.40% to $0.3410 with more than 72.93 million shares, compared to its average volume of 3.23 million shares. The stock moved within a range of $0.3350…


Stocks Poised to Pop Wednesday: SRCO, ANPC, REDU, TTOO, VIVE, STAB

Following were the notable penny stock buzzers in the previous session on high volume. Keep an eye on these stocks this week. If you are interested in nanocap stocks here is one you should look into Sparta Commercial Services Inc. (OTCMKTS:SRCO) just launched SpartaPayIQ, a crypto payment gateway developed for e-commerce and brick & mortar businesses.  SpartaPayIQ makes SRCO makes a ‘first of its kind’ vertically integrated crypto commerce company….

April 13, 2022

Statera Biopharma (NASDAQ:STAB) Prices Public Offering: Stock Tanks

March 25, 2022

In the past week, the Statera Biopharma (NASDAQ:STAB) stock has declined sharply amidst a heavy selloff and dived by as much as 45%. Considering the sheer magnitude of the decline in the Statera stock, it may be a good idea for investors to perhaps figure out if the free fall is going to continue or if there is going to be any recovery any time soon. Trading Data On Thursday,…